-
1 Comment
IDEAYA Biosciences, Inc is currently in a long term downtrend where the price is trading 3.3% below its 200 day moving average.
From a valuation standpoint, the stock is 97.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 30.2.
IDEAYA Biosciences, Inc's total revenue rose by inf% to $11M since the same quarter in the previous year.
Its net income has increased by 100.0% to $-5K since the same quarter in the previous year.
Finally, its free cash flow fell by 32.8% to $-12M since the same quarter in the previous year.
Based on the above factors, IDEAYA Biosciences, Inc gets an overall score of 3/5.
| CurrencyCode | USD |
|---|---|
| ISIN | US45166A1025 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Dividend Yield | None |
|---|---|
| Target Price | 52.25 |
| Market Cap | 2B |
| Beta | 0.51 |
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for IDYA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
